仿制药研发商MS Pharma获得股权融资-动脉网

MS Pharma Announces Strategic Growth Investment from Olayan Financing Company

CISION 等信源发布 2026-05-18 19:52



可切换为仅中文







Strategic Partnership to Accelerate Growth in Saudi Arabia and Across the MENA Region

战略合作加速沙特阿拉伯和中东及北非地区的增长

AMMAN, Jordan and RIYADH, Saudi Arabia

约旦安曼和沙特阿拉伯利雅得

，

May 18, 2026

2026年5月18日

/PRNewswire/ -- MS Pharma today announced that Olayan Financing Company (OFC) has made a minority equity investment in the company. This partnership brings strategic depth to MS Pharma's next phase of growth, underscoring its commitment to innovation, regional expansion, and long-term value creation.

/PRNewswire/ -- MS Pharma今天宣布，奥拉扬融资公司（OFC）已对公司进行了少数股权投资。这一合作为MS Pharma下一阶段的增长带来了战略深度，彰显了其对创新、区域扩张和长期价值创造的承诺。

It also marks the beginning of a long-term partnership between OFC and MS Pharma's existing majority shareholders, who have distinguished themselves through decades of leadership and excellence in the pharmaceutical sector..

它还标志着OFC与MS Pharma现有大股东之间长期合作关系的开始，这些股东通过在制药行业几十年的领导地位和卓越表现脱颖而出。

继续阅读

The signing ceremony marks a new phase of collaboration between MS Pharma and Olayan Financing Company.

签约仪式标志着MS Pharma与Olayan融资公司合作的新阶段。

Officials from MS Pharma and Olayan Financing Company during the signing ceremony announcing OFC’s partnership with MS Pharma.

MS Pharma和Olayan融资公司的官员在签署仪式上宣布OFC与MS Pharma的合作关系。

The transaction involves MS Pharma issuing new share capital in exchange for a substantial cash investment from OFC, resulting in OFC acquiring a minority stake in the company.

该交易涉及MS Pharma发行新股以换取OFC的大量现金投资，从而使OFC获得公司少数股权。

The investment strengthens MS Pharma's financial position and flexibility to advance its ambitious growth plans in the MENA region, supporting the expansion of its biosimilars portfolio, manufacturing capabilities, and supply chain resilience across MENA to better serve patients, healthcare providers, and partners across the region..

这项投资加强了MS Pharma的财务地位和灵活性，以推进其在中东和北非地区的宏伟增长计划，支持其生物仿制药组合、制造能力以及整个中东和北非地区供应链的扩展和弹性，从而更好地服务该地区的患者、医疗保健提供者和合作伙伴。

Commenting on the new partnership,

在谈到新的合作伙伴关系时，

Ghiath Sukhtian, Chairman of MS Pharma,

齐亚斯·苏赫蒂安，MS制药公司董事长，

said

说

：

'We are delighted and honored to welcome OFC as partners in the company. Their global operational and investing expertise, as well as their deep roots in KSA, will add significant value to MS Pharma and benefit all our stakeholders. This investment reflects the exceptional quality and commitment of our people across the organization, whose leadership and consistent execution have been instrumental in building MS Pharma into the platform it is today.'.

“我们非常高兴并深感荣幸欢迎OFC成为公司的合作伙伴。他们在全球运营和投资方面的专业能力，以及在沙特阿拉伯的深厚根基，将为MS Pharma增添显著价值，并使我们所有利益相关者受益。这项投资反映了我们整个组织员工卓越的品质和承诺，他们的领导力和始终如一的执行力对将MS Pharma打造成今天这样的平台起到了关键作用。”

Kalle Kaend, CEO of MS Pharma, added:

卡尔·肯德，MS制药公司的首席执行官，补充道：

'This investment comes at an exciting inflection point for MS Pharma. It will enable us to deepen our expertise in biologics, expand our reach in KSA and the wider MENA region, and accelerate our growth in biosimilars. We look forward to leveraging OFC's experience and established network across KSA to achieve our ambitious goals while continuing to build a high-performing organization that delivers long-term value to patients, partners, and our employees.'.

“这项投资正值MS Pharma令人振奋的转折点。它将使我们能够加深在生物制品领域的专业知识，扩大我们在沙特阿拉伯和更广泛的中东及北非地区的影响力，并加速我们在生物类似药领域的增长。我们期待利用OFC在沙特阿拉伯的丰富经验和广泛网络，实现我们的宏伟目标，同时继续打造一个高效能的组织，为患者、合作伙伴和员工提供长期价值。”

Nabeel Al-Amudi, CEO of Olayan Financing Company,

奥拉扬融资公司首席执行官纳比尔·阿勒阿穆迪，

remarked

评论道

：

'MS Pharma has established itself as a leading pharmaceutical platform in the region, with strong capabilities across generics and biologics. We are pleased to partner with the company at this stage of its growth and look forward to supporting its continued expansion in Saudi Arabia and across the MENA region, in alignment with our long-term investment philosophy.'.

“MS Pharma 已经成为该地区领先的制药平台，拥有强大的仿制药和生物制品能力。我们很高兴在此增长阶段与该公司合作，并期待支持其在沙特阿拉伯和整个中东及北非地区的持续扩展，这与我们的长期投资理念相契合。”

The partnership builds on MS Pharma's leadership in biosimilars, particularly in KSA, where its biologics site became the first in the Kingdom to receive SFDA GMP approval for biologics manufacturing. This year, the company also plans to become the first supplier of locally manufactured biologics to the Saudi market.

该合作伙伴关系建立在MS Pharma在生物仿制药领域的领导地位之上，尤其是在沙特阿拉伯，其生物制品基地成为沙特首个获得SFDA GMP生物制品生产认证的机构。今年，该公司还计划成为沙特市场首个本地制造生物制品的供应商。

These milestones reinforce the company's commitment to localization under the Saudi National Biotechnology Strategy and Vision 2030. Through the expansion of high-quality biologic therapies across the region and close collaboration with regional and international health authorities, MS Pharma remains dedicated to the highest standards of regulatory excellence and quality..

这些里程碑进一步强化了该公司在沙特国家生物技术战略和2030愿景下对本地化的承诺。通过在整个地区扩展高质量的生物疗法，并与区域和国际卫生当局密切合作，MS Pharma始终致力于达到最高的监管卓越和质量标准。

MS Pharma also aims to deepen collaboration with global development and licensing partners, offering its manufacturing capabilities to support export into global markets.

MS Pharma还旨在深化与全球开发和许可合作伙伴的合作，提供其制造能力以支持出口到全球市场。

About MS Pharma

关于MS Pharma

MS Pharma is a leading regional pharmaceutical company in the MENA region, specializing in the development, production, and distribution of a broad portfolio of generic and biologic therapies. Positioned for rapid growth, the company operates five manufacturing facilities across Jordan, Algeria, and Saudi Arabia, including a newly launched biologics plant serving the broader MENA market..

MS Pharma 是 MENA 地区领先的区域性制药公司，专注于开发、生产和分销广泛的产品组合，包括仿制药和生物疗法。公司定位为快速增长，在约旦、阿尔及利亚和沙特阿拉伯运营着五家生产设施，其中包括一家新推出的生物制品工厂，服务于更广泛的 MENA 市场。

Headquartered in Amman, Jordan, with management offices in Zug, Switzerland, MS Pharma employs over 2,000 people across 12 countries and is committed to improving patient access to high-quality, affordable medicines.

总部位于约旦安曼，管理办公室在瑞士楚格，MS Pharma 在12个国家拥有超过2000名员工，致力于改善患者获得高质量、可负担药品的机会。

For more information, please visit

更多信息，请访问

www.mspharma.com

。

About Olayan Financing Company (OFC)

关于奥拉扬融资公司 (OFC)

The Olayan conglomerate came into being in 1947 when its founder, Suliman Saleh Olayan, established its progenitor company, a company that endures to date under the Olayan Financing Company (OFC), a leading multinational enterprise with a diversified portfolio of over 32 companies and global investments that extend across Saudi Arabia, the wider Middle East, North Africa, Turkey, and India.

1947年，奥拉扬集团的创始人苏里曼·萨利赫·奥拉扬成立了其前身公司，该集团由此诞生。这家前身公司至今仍然存在，即奥拉扬融资公司（OFC），这是一家领先的跨国企业，拥有超过32家公司的多元化投资组合，其全球投资遍布沙特阿拉伯、更广泛的中东地区、北非、土耳其和印度。

A long-term strategic investor.

长期战略投资者。

，

OFC's investments extend to public equities, private equities, strategic partnerships, and real estate assets as well as the portfolio of one of its main investments, Olayan Saudi Holding Company, which operates across five sectors powered by its many long-standing partnerships that have endured for several decades.

OFC的投资涵盖了上市股票、私人股权、战略合作伙伴关系、房地产资产，以及其主要投资之一——奥拉扬沙特控股公司 (Olayan Saudi Holding Company) 的投资组合。该公司横跨五大领域开展业务，依托众多长期合作伙伴关系，这些合作关系已持续数十年之久。

OFC's multicultural workforce comprises more than 14,500 qualified professionals, representing over 60 nationalities. In line with its commitment to creating a long-term positive impact on society, OFC's philanthropy arm, the Suliman S. Olayan Foundation (SSOF), supports a broad range of education, healthcare, and community outreach initiatives.

OFC的多元文化员工队伍由超过14,500名合格的专业人员组成，代表60多个国家。为履行对社会产生长期积极影响的承诺，OFC的慈善机构苏利曼·S·奥拉扬基金会（SSOF）支持广泛的教育、医疗和社区拓展计划。

As a Saudi company, OFC actively contributes to Vision 2030's economic diversification, local content, talent development, and circular economy goals..

作为沙特公司，OFC 积极助力实现“2030 愿景”中的经济多元化、本地化内容、人才培养和循环经济目标。

For more information, please visit

欲了解更多信息，请访问

www.ofc.com

。

Photo:

照片：

https://mma.prnewswire.com/media/2982117/MS_Pharma_Olayan_Financing.jpg

Photo:

照片：

https://mma.prnewswire.com/media/2982116/MS_Pharma_Olayan_Financing_1.jpg

SOURCE MS Pharma